Astellas Applies For Approval Of Irribow For IBS With Diarrhea
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharmaceuticals announced Aug. 8 it applied for a domestic application for approval of orally disintegrating tablets of Irribow (ramosetron) to treat irritable bowel syndrome with diarrhea.